留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝移植术后乙型肝炎病毒再激活的分子机制研究进展

杨健 谢炎 田大治 张骊 张洋铭 蒋文涛

杨健, 谢炎, 田大治, 等. 肝移植术后乙型肝炎病毒再激活的分子机制研究进展[J]. 器官移植, 2020, 11(2): 298-303. doi: 10.3969/j.issn.1674-7445.2020.02.019
引用本文: 杨健, 谢炎, 田大治, 等. 肝移植术后乙型肝炎病毒再激活的分子机制研究进展[J]. 器官移植, 2020, 11(2): 298-303. doi: 10.3969/j.issn.1674-7445.2020.02.019
Yang Jian, Xie Yan, Tian Dazhi, et al. Research progress on molecular mechanism of hepatitis B virus reactivation after liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 298-303. doi: 10.3969/j.issn.1674-7445.2020.02.019
Citation: Yang Jian, Xie Yan, Tian Dazhi, et al. Research progress on molecular mechanism of hepatitis B virus reactivation after liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 298-303. doi: 10.3969/j.issn.1674-7445.2020.02.019

肝移植术后乙型肝炎病毒再激活的分子机制研究进展

doi: 10.3969/j.issn.1674-7445.2020.02.019
基金项目: 

国家自然科学基金面上项目 81870444

天津市科委慢性病防治科技重大专项 17ZXMFSY00040

天津市第一中心医院春蕾计划 CL201801

天津市自然科学基金 19JCQNJC10300

详细信息
    作者简介:

    杨健,男,1987年生,博士,医师,研究方向为器官移植,Email:yangjian0628@126.com

    通讯作者:

    蒋文涛,男,1974年生,博士,主任医师,研究方向为器官移植,Email:447660280@qq.com

  • 中图分类号: R617, R373.21

Research progress on molecular mechanism of hepatitis B virus reactivation after liver transplantation

More Information
  • 摘要: 肝移植是治疗乙型病毒性肝炎(乙肝)相关性肝衰竭、肝硬化和肝细胞癌(肝癌)的最有效方法。然而,肝移植术后乙型肝炎病毒(HBV)再激活不利于移植肝功能恢复且导致预后不良,其防治问题是当前内、外科医师研究的焦点。目前的病毒抑制策略不能完全根除HBV,也不能完全预防HBV在未来复发感染。本文旨在探讨肝移植术后HBV再激活的分子机制,以期更有效预防肝移植术后乙肝复发。

     

  • [1] STOCKDALE AJ, MITAMBO C, EVERETT D, et al. Epidemiology of hepatitis B, C and D in Malawi: systematic review[J]. BMC Infect Dis, 2018, 18(1):516. DOI: 10.1186/s12879-018-3428-7.
    [2] HIBI T, SUGAWARA Y. Locoregional therapy as a bridge to liver transplantation for hepatocellular carcinoma within Milan criteria: from a transplant oncology viewpoint[J]. Hepatobiliary Surg Nutr, 2018, 7(2):134-135. DOI: 10.21037/hbsn.2018.01.07.
    [3] BODZIN AS, BAKER TB. Liver transplantation today: where we are now and where we are going[J]. Liver Transpl, 2018, 24(10):1470-1475. DOI: 10.1002/lt.25320.
    [4] TAHARA H, OHDAN H. HBV reactivation after liver transplantation and the management strategies[J]. Nihon Rinsho, 2015, 73 (Suppl 9):550-554. http://cn.bing.com/academic/profile?id=d402e9ce2f5365994b57558ba5a85f2e&encoded=0&v=paper_preview&mkt=zh-cn
    [5] SORIANO V, BARREIRO P, BENITEZ L, et al. New antivirals for the treatment of chronic hepatitis B[J]. Expert Opin Investig Drugs, 2017, 26(7):843-851. DOI: 10.1080/13543784.2017.1333105.
    [6] MAIER M, LIEBERT UG, WITTEKIND C, et al. Clinical relevance of minimal residual viremia during long-term therapy with nucleos(t)ide analogues in patients with chronic hepatitis B[J]. PLoS One, 2013, 8(6):e67481. DOI: 10.1371/journal.pone.0067481.
    [7] LI X, ZHAO J, YUAN Q, et al. Detection of HBV covalently closed circular DNA[J]. Viruses, 2017, 9(6):139. DOI: 10.3390/v9060139.
    [8] KASRAIANFARD A, WATT KD, LINDBERG L, et al. HBIG remains significant in the era of new potent nucleoside analogues for prophylaxis against hepatitis B recurrence after liver transplantation[J]. Int Rev Immunol, 2016, 35(4):312-324. http://www.ncbi.nlm.nih.gov/pubmed/24911598
    [9] CHAUHAN R, LINGALA S, GADIPARTHI C, et al. Reactivation of hepatitis B after liver transplantation: current knowledge, molecular mechanisms and implications in management[J]. World J Hepatol, 2018, 10(3):352-370. DOI: 10.4254/wjh.v10.i3.352.
    [10] LIU S, ZHOU B, VALDES JD, et al. Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection[J]. Hepatology, 2019, 69(4):1816-1827. DOI: 10.1002/hep.30325.
    [11] WONG DK, SETO WK, FUNG J, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency[J]. Clin Gastroenterol Hepatol, 2013, 11(8):1004-1010. DOI: 10.1016/j.cgh.2013.01.026.
    [12] PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study[J]. Gut, 2011, 60(8):1109-1116. DOI: 10.1136/gut.2010.221846.
    [13] GENTILE G, ANDREONI M, ANTONELLI G, et al. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review[J]. Clin Microbiol Infect, 2017, 23(12):916-923. DOI: 10.1016/j.cmi.2017.06.024.
    [14] LIN CL, KAO JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants[J]. Best Pract Res Clin Gastroenterol, 2017, 31(3):249-255. DOI: 10.1016/j.bpg.2017.04.010.
    [15] ITO K, YONEDA M, SAKAMOTO K, et al. Virological and clinical characteristics of hepatitis B virus genotype A[J]. J Gastroenterol, 2018, 53(1):18-26. DOI: 10.1007/s00535-017-1367-5.
    [16] UZ-ZAMAN MH, RAHMAN A, YASMIN M. Epidemiology of hepatitis B virus infection in Bangladesh: prevalence among general population, risk groups and genotype distribution[J]. Genes (Basel), 2018, 9(11):541. DOI: 10.3390/genes9110541.
    [17] YEH CT, LIANG KH, CHANG ML, et al. Phenotypic and genotypic shifts in hepatitis B virus in treatment-naive patients, Taiwan, 2008-2012[J]. Emerg Infect Dis, 2017, 23(5):820-821. DOI: 10.3201/eid2305.161894.
    [18] HASSEMER M, FINKERNAGEL M, PEIFFER KH, et al. Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes[J]. Virology, 2017, 502:1-12. DOI: 10.1016/j.virol.2016.12.003.
    [19] LI X, LIU Y, XIN S, et al. Comparison of detection rate and mutational pattern of drug-resistant mutations between a large cohort of genotype B and genotype C hepatitis B virus-infected patients in north China[J]. Microb Drug Resist, 2017, 23(4):516-522. DOI: 10.1089/mdr.2016.0093.
    [20] GOYAL A, MURRAY JM. Roadmap to control HBV and HDV epidemics in China[J]. J Theor Biol, 2017, 423:41-52. DOI: 10.1016/j.jtbi.2017.04.007.
    [21] COUTO I, VICTORIA M, VELOSO VG, et al. Prevalence and predictors for compensated advanced chronic liver disease (c-ACLD) in patients with chronic hepatitis delta virus (HDV) infection[J]. PLoS One, 2017, 12(3):e0174453. DOI: 10.1371/journal.pone.0174453.
    [22] STROFFOLINI T, SAGNELLI E, SAGNELLI C, et al. Hepatitis delta infection in Italian patients: towards the end of the story?[J]. Infection, 2017, 45(3):277-281. DOI: 10.1007/s15010-016-0956-1.
    [23] RICCO G, POPA DC, CAVALLONE D, et al. Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection[J]. J Viral Hepat, 2018, 25(8):911-919. DOI: 10.1111/jvh.12895.
    [24] LUPIA T, CORCIONE S, BOGLIONE L, et al. Visceral leishmaniasis in a patient with active HBV/HDV co-infection[J]. J Infect Public Health, 2020, 13(2):306-308. DOI: 10.1016/j.jiph.2019.07.026.
    [25] PEREZ-VARGAS J, AMIRACHE F, BOSON B, et al. Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo[J]. Nat Commun, 2019, 10(1):2098. DOI: 10.1038/s41467-019-10117-z.
    [26] YURDAYDIN C, ABBAS Z, BUTI M, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy[J]. J Hepatol, 2019, 70(5):1008-1015. DOI: 10.1016/j.jhep.2018.12.022.
    [27] HÖNER ZU SIEDERDISSEN C, CORNBERG M. Management of HBV and HBV/HDV-associated liver cirrhosis[J]. Visc Med, 2016, 32(2):86-94. DOI: 10.1159/ 000445518.
    [28] JIANG Z, FENG X, ZHANG W, et al. Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients[J]. Liver Int, 2007, 27(9):1202-1208. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=470f553a1726f1d52eb519137ec169e6
    [29] XIA C, LU M, ZHANG Z, et al. TLRs antiviral effect on hepatitis B virus in HepG2 cells[J]. J Appl Microbiol, 2008, 105(5):1720-1727. DOI: 10.1111/j.1365-2672.2008. 03896.x.
    [30] JIANG M, BROERING R, TRIPPLER M, et al. Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen[J]. J Viral Hepat, 2014, 21(12):860-872. DOI: 10.1111/jvh.12216.
    [31] TESTONI B, LEVRERO M, ZOULIM F. Challenges to a cure for HBV infection[J]. Semin Liver Dis, 2017, 37(3):231-242. DOI: 10.1055/s-0037-1606212.
    [32] SUNG WK, ZHENG H, LI S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma[J]. Nat Genet, 2012, 44(7):765-769. DOI: 10.1038/ng.2295.
    [33] CHAUHAN R, CHURCHILL ND, MULROONEY-COUSINS PM, et al. Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma[J]. Oncogenesis, 2017, 6(4):e317. DOI: 10.1038/oncsis.2017.22.
    [34] COUGOT D, NEUVEUT C, BUENDIA MA. HBV induced carcinogenesis[J]. J Clin Virol, 2005, 34 (Suppl 1):S75-S78. http://d.old.wanfangdata.com.cn/Periodical/gxykdx200102001
    [35] MARUSAWA H, UEMOTO S, HIJIKATA M, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen[J]. Hepatology, 2000, 31(2):488-495. doi: 10.1002/hep.510310232
    [36] XUAN SY, SUN Y, ZHANG J. The influence to the function of cellular immunity after being infected by HBV in the PBMC in chronic hepatitis B[J]. Chin J Epidemiol, 1997, 18(2):80-82. http://cn.bing.com/academic/profile?id=46a636ad47400a355ec33ff5657947b0&encoded=0&v=paper_preview&mkt=zh-cn
    [37] COFFIN CS, MULROONEY-COUSINS PM, PETERS MG, et al. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy[J]. J Viral Hepat, 2011, 18(6):415-423. DOI: 10.1111/j.1365-2893.2010.01321.x.
    [38] BUDZINSKA MA, SHACKEL NA, URBAN S, et al. Cellular genomic sites of hepatitis B virus DNA integration[J]. Genes (Basel), 2018, 9(7):365. DOI: 10.3390/genes9070365.
    [39] GATTA A, GIANNINI C, LAMPERTICO P, et al. Hepatotropic viruses: new insights in pathogenesis and treatment[J]. Clin Exp Rheumatol, 2008, 26(1 Suppl 48): S33-S38. http://cn.bing.com/academic/profile?id=b2074f0be7c58145999b2f850f792fd2&encoded=0&v=paper_preview&mkt=zh-cn
    [40] VLACHOGIANNAKOS J, PAPATHEODORIDIS GV. Hepatitis B: who and when to treat?[J]. Liver Int, 2018, 38 (Suppl 1):71-78. DOI: 10.1111/liv.13631.
    [41] HUANG W, ZHAO F, HUANG Y, et al. Rapamycin enhances HBV production by inducing cellular autophagy[J]. Hepat Mon, 2014, 14(10):e20719. DOI: 10.5812/hepatmon.20719.
    [42] BRENNAN DC, AGUADO JM, POTENA L, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms[J]. Rev Med Virol, 2013, 23(2):97-125. DOI: 10.1002/rmv.1733.
    [43] 于乐成, 范晔, 李平等.与直接抗病毒药物应用相关的HCV/HBV双重感染的特点及其诊治管理[J].临床肝胆病杂志, 2018, 34(2):238-241. DOI: 10.3969/j.issn.1001-5256.2018.02.004.

    YU LC, FAN Y, LI P, et al. Features and management of patients with hepatitis C virus/hepatitis B virus dual infection associated with the application of direct-acting antiviral agents[J]. J Clin Hepatol, 2018, 34(2):238-241. DOI: 10.3969/j.issn.1001-5256.2018.02.004.
  • 加载中
计量
  • 文章访问数:  86
  • HTML全文浏览量:  6
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-12-20
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-03-15

目录

    /

    返回文章
    返回